NICE National Institute for Health and Care Excellence

NICE guidance

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)

Technology appraisal guidance
Published: 22 July 2015

www.nice.org.uk/guidance/ta351

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy because no evidence submission was received from The Medicines Company.

Background

The Medicines Company was invited to submit evidence for this single technology appraisal for cangrelor in October 2014.

The company informed NICE that it would not be providing an evidence submission because there was insufficient data to develop the appropriate cost-effectiveness assessment of cangrelor for the population covered in the marketing authorisation, that is, adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. If, after doing this, organisations still wish to consider cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy, they should follow the advice set out in NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable. NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

ISBN: 978-1-4731-1341-1